Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
Sport9 hours ago
Quartararo eyes MotoGP title as Rossi waves goodbye to Misano – NEWS.com.au
Western News7 hours ago
Medical practitioner liability – Proctor
Business6 hours ago
Own Woolworths (ASX:WOW) shares? Here’s why the company is in the news
Western News3 hours ago
It’s bee a rough year for many — send us some good vibes Today we’re chuffed fo…